New Cancer Rx: $32,000 Per Month

Blueprint Medicines Corp received its first-ever FDA approval Thursday for a treatment for a rare, genetically linked form of gastrointestinal cancer. A 30-day supply will cost $32,000. Blueprint plans to submit three other drugs for FDA approval by the end of the year. – Boston Business Journal

Jan 9, 2020 |

Reuters – The U.S. Food and Drug Admin. approved Blueprint Medicines Corp’s oral therapy to treat a rare form of cancer that affects the stomach and small intestine, the agency said on Thursday.

The FDA’s decision makes the therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor (GIST).

Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage.

The list price is not necessarily what patients actually pay as “out-of-pocket” costs vary based on the duration of the treatment and individual healthcare plans.

...article continued below
- Advertisement -

GIST tumors, which usually begin in the stomach or small intestine, are a type of soft-tissue sarcoma.

Patients are at risk of the cancer recurring even after successful surgery to remove tumors.

About 5,000 Americans are diagnosed with the cancer every year. With Ayvakit, Blueprint is looking to target about 6% of these patients whose cancers are driven by PDGFRA exon 18 mutations.

In patients with the mutation, the cancer tends to progress in about three to four months after being treated with currently available therapies … Read more. 


...article continued below
- Advertisement -

Big Pharma Rings In 2020 With Price Hikes On 250 Rx

Price-Gouging Pharma Co. Recalls Adulterated Rx

Trump: $17,850 Urine Tests, Other Abuses Must End

MORE OF TODAY’S TOP HEALTH NEWS: Sex As Therapy | Fungus Resistant To ALL Rx | $32K/Mo. Cancer Rx | $2 Mil. Settlement; Patients Won’t Get A Dime

- Advertisement -


Who Needs a COVID Booster Shot, According To Science

SCIENTIFIC AMERICAN – It’s a question on many people’s minds these days: Do I need a booster dose of a COVID vaccine? The answer, like...

Navy Identifies 15th Sailor Killed By COVID-19

THE HILL – A Navy sailor who died of coronavirus-related complications earlier this month has been identified. Master-at-Arms Senior Chief Michael Haberstumpf, 42, of Whispering...

It’s Like a Fitbit, But for Your Penis

INSIDE HOOK – In a season three episode of Sex and the City, Charlotte attempts to get to the bottom of her husband’s impotence...

Fauci’s Agency Admits Funding Wuhan Lab Experiments

(National Review) A top NIH official admitted in a Wednesday letter that U.S. taxpayers funded gain-of-function research on bat coronaviruses in Wuhan. The letter went on...

Doctor Accused Of Bad Penis And Breast Enhancements Loses License

NJ.com – New Jersey authorities have shut down the license of a doctor on accusations he was improperly performing penile and breast enhancement procedures,...

Pig Organ Transplant Experiment Performed On Brain-Dead New Yorker

AP – Scientists temporarily attached a pig's kidney to a human body and watched it begin to work, a small step in the decades-long...

FL Chief Fired for Not Forcing Firefighter Vaccinations

A Florida battalion chief has been fired for refusing to discipline workers who hadn't gotten a COVID-19 vaccine in violation of a requirement for county employees.

Italian Study Details Who Dies of COVID If Vaccinated

People vaccinated against COVID-19 are highly unlikely to die of the disease unless very old and already badly ill before getting it, a study in Italy showed on Wednesday.

Clinton ‘Touched By The Outpouring Of Support’

CHAPPAQUA, N.Y. (AP) — Former President Bill Clinton released a video saying he is on the road to recovery after being hospitalized in Southern...

New Hooters Uniforms: Do They Go Too Far?

DAILY DOT – Hooters is reportedly making a new part of its uniform optional after some employees critiqued it on TikTok. Over the last week or...
- Advertisement -